• Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression 

  Lheureux, Stephanie; Prokopec, Stephenie; Oldfield, Leslie E.; Gonzalez-Ochoa, Eduardo; Bruce, Jeff; Wong, Derek; OAKNIN, ANA (American Association for Cancer Research, 2023-09-15)

• Transfusion-transmission of hepatitis E virus through red blood cell transfusion but not through platelet concentrates: A case report from Spain 

  Ojea, Ana María; Seco, Carolina; Mata, Pablo; Muñoz, María del Carmen; Álvarez Argüelles, Marta Elena; RODRIGUEZ-FRIAS, FRANCISCO; QUER, JOSEP; Rando Segura, Ariadna (Wiley, 2023-09)

• The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program 

  Levink, Iris; Jaarsma, Sanne C.; Koopmann, Brechtje D. M.; van Riet, Priscilla; Overbeek, Kasper; Meziani, Jihane; Pando, Elizabeth (Wiley, 2023-09)

• Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain 

  Moreno, Santiago; Rivero Román, Antonio; Ventayol, Pere; Falcó, Vicenç; Torralba, Miguel; Schroeder, Melanie (Springer, 2023-08)

• Cost-effectiveness of Direct Transfer to Angiography Suite of Patients With Suspected Large Vessel Occlusion 

  Nguyen, Chi; Lahr, Maarten; van der Zee, Durk-Jouke; van Voorst, Henk; Roos, Yvo; Ribo, Marc (Wolters Kluwer Health, 2023-09-05)

View more